How to Make the Most of Drugs We Already Have image

The Upshot, New York Times, February 22, 2016
By Austin Frakt, citing Ben Roin (Academic Fellow alumnus)

Links

Read the Full Article

From the article

[...] Moreover, if a drug company cannot ascertain the problem for which a prescription is written, it lacks the means by which it can enforce its new patent. Therefore, it cannot recoup, through higher prices, expenses for investing in new-use research.

This is a solvable problem, says Benjamin Roin, assistant professor of technological innovation, entrepreneurship and strategic management at M.I.T. He suggested a universal electronic prescribing system that tracks prescriptions and conditions for which they’re intended. This is feasible and exists in Quebec. With such a system in place, a new-use innovator could charge more for the patented new use, and it would be easier to tell when a competitor is breaking the law by selling its product for that use. [...]

biotechnology health care reform intellectual property pharmaceuticals